Pharmacokinetic Modeling and Simulation of Procainamide and N-Acetylprocainamide in a Patient Receiving Continuous Renal Replacement Therapy: A Novel.

Slides:

Advertisements

Similar presentations

The Rise of Renal Pathology in Nephrology: Structure Illuminates Function Vivette D. D'Agati, MD, Michael Mengel, MD American Journal of Kidney Diseases.

Advertisements

The Pharmacokinetics of Intradialytic Administration of Eculizumab in an Infant Ji Lee, PharmD, Peace Imani, MD, Jessica Geer, C-PNP, Michael Braun, MD,

Quiz Page June 2007 American Journal of Kidney Diseases

Renal Function Testing

Gregory L. Hundemer, MD, MPH, Andrew Z. Fenves, MD, Kristy M

Development of Reduced Kidney Function in Rheumatoid Arthritis

Quiz Page March 2008 American Journal of Kidney Diseases

Measuring GFR Using the Plasma Clearance of 99mTc-DTPA

Caring for Undocumented Immigrants With Kidney Disease

This Month in AJKD American Journal of Kidney Diseases

Management of Acute Kidney Injury: Core Curriculum 2018

Estevão Bassi, MD, Cesar B

Renal Manifestations of Plasma Cell Disorders

The Challenge of Providing Renal Replacement Therapy in Developing Countries: The Latin American Perspective Gregorio T. Obrador, MD, MPH, Ximena Rubilar,

Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A Dialysis Provider’s Perspective J. Michael Lazarus, MD, Raymond M. Hakim,

Solute-Solver: A Web-Based Tool for Modeling Urea Kinetics for a Broad Range of Hemodialysis Schedules in Multiple Patients John T. Daugirdas, MD, Thomas.

Sevelamer Prescriptions After Reporting of the Dialysis Clinical Outcomes Revisited (DCOR) Trial Findings: An Analysis of 5,495 Patients Receiving Maintenance.

James E. Novak, Khalid Alamiri, Jerry Yee

Evaluation of the Potential Living Kidney Donor

Hai-yan Wang, MD, American Journal of Kidney Diseases

Focusing on Health Literacy Might Help Us Cross the Quality Chasm

Salt and Hypertension American Journal of Kidney Diseases

Quiz Page July 2007 American Journal of Kidney Diseases

Felicity C. Smith, BMedSci (Hons), Shaun S. Kumar, PhD, Timothy J

The Use of N-of-1 Trials to Individualize Treatment in Patients With Renal Magnesium Wasting Anneke P. Bech, MD, Jack F.M. Wetzels, MD, Hans Groenewoud,

Hemoglobin Level and Transfusions in Patients on Maintenance Dialysis: Where the Rubber Meets the Road Eduardo Lacson, MD, MPH, Franklin Maddux, MD

This Month in AJKD American Journal of Kidney Diseases

Factors Influencing Route of Administration for Epoetin Treatment Among Hemodialysis Patients in the United States Mae Thamer, PhD, Yi Zhang, DDS, MS,

Drug Dosing Considerations in Alternative Hemodialysis

The Map Is Not the Territory—Mapping Out the Course and Cost of CKD

Pharmacokinetics of Multiple-Dose Levofloxacin in Hemodialysis Patients Shuichi Tsuruoka, MD, PhD, Noritsugu Yokota, MD, PhD, Tokie Hayasaka, RN, Tetsuo.

Use of Diuretics in Heart Failure: A Precarious Balance

Elevated Fibroblast Growth Factor 23 in a Patient With Metastatic Prostate Cancer and Hypophosphatemia Casey L. Cotant, MD, Panduranga S. Rao, MD, DNB,

Quiz page December 2004 American Journal of Kidney Diseases

Salicylate Intoxication as a Cause of Pseudohyperchloremia

David J. Leehey, MD, Tony Casini, MS, Donald Massey, DO

This Month in AJKD American Journal of Kidney Diseases

American Journal of Kidney Diseases

Quiz Page April 2008 American Journal of Kidney Diseases

Study Designs in Patient-Oriented Research

Drug Dose Adjustments in Patients With Renal Impairment

Pharmacokinetics and Pharmacodynamics of Imipenem and Meropenem in Critically Ill Patients Treated With Continuous Venovenous Hemodialysis David Afshartous,

Dmytro Khadzhynov, MD, Christian Joukhadar, MD, Harm Peters, MD

Erratum American Journal of Kidney Diseases

Daniel E. Weiner, MD, MS, Mark J. Sarnak, MD, MS

Thiazide Responsiveness Testing in Patients With Renal Magnesium Wasting and Correlation With Genetic Analysis: A Diagnostic Test Study Anneke P. Bech,

Quiz Page August 2007 American Journal of Kidney Diseases

Trial Quality in Nephrology: How Are We Measuring Up?

Kim Dao, MD, Haithem Chtioui, MD, Yimin Lu, MD, Cody J

Removal of Dabigatran by Hemodialysis

Multidrug-Resistant Organisms Within the Dialysis Population: A Potentially Preventable Perfect Storm David P. Calfee, MD, MS American Journal of Kidney.

American Journal of Kidney Diseases

Erratum American Journal of Kidney Diseases

In the Literature: Cognitive Impairment in Hemodialysis Patients

Achieving Fairness in Access to Kidney Transplant: A Work in Progress

Increased Urinary Albumin Excretion Following Recovery From Thrombotic Thrombocytopenic Purpura Due to Acquired ADAMTS13 Deficiency Dustin J. Little,

This Month in AJKD American Journal of Kidney Diseases

Quiz Page June 2009 American Journal of Kidney Diseases

James F. Winchester, MD, Thomas H. Hostetter, MD, Timothy W. Meyer, MD

Quiz Page June 2011 American Journal of Kidney Diseases

This Month in AJKD American Journal of Kidney Diseases

Quiz Page November 2005 American Journal of Kidney Diseases

American Journal of Kidney Diseases

Dialysis Research and N-of-1 Trials: Made for Each Other?

Quiz Page January 2010 American Journal of Kidney Diseases

Clinical Practice Recommendations For Peritoneal Dialysis Adequacy

Maristela Böhlke, PhD American Journal of Kidney Diseases

Clinical Practice Guidelines for Peritoneal Dialysis Adequacy

Quiz page December 2003 American Journal of Kidney Diseases

This Month in AJKD American Journal of Kidney Diseases

Presentation transcript:

Pharmacokinetic Modeling and Simulation of Procainamide and N-Acetylprocainamide in a Patient Receiving Continuous Renal Replacement Therapy: A Novel Approach to Guide Renal Dose Adjustments Ahmed N. Mohamed, PhD, Ahmed M. Abdelhady, MS, Dustin Spencer, PharmD, Kevin M. Sowinski, PharmD, James E. Tisdale, PharmD, Brian R. Overholser, PharmD American Journal of Kidney Diseases Volume 61, Issue 6, Pages 1046-1048 (June 2013) DOI: 10.1053/j.ajkd.2013.02.358 Copyright © 2013 Terms and Conditions

Figure 1 Simulated plasma concentration-time profiles after 3 different dosing regimens with 30-minute loading and 48-hour maintenance doses. (A) Loading dose: 20 mg/min; maintenance dose: 4 mg/min. (B) Loading dose: 20 mg/min; maintenance dose: 2 mg/min. (C) Loading dose: 20 mg/min; maintenance dose: 1 mg/min. The horizontal solid and dashed lines represent therapeutic ranges for procainamide and combined procainamide/NAPA concentrations, respectively. American Journal of Kidney Diseases 2013 61, 1046-1048DOI: (10.1053/j.ajkd.2013.02.358) Copyright © 2013 Terms and Conditions